natgillin/translations-raw huggingface dataset:
In the study investigating the effects on hot flushes, treatment with Duavive (conjugated oestrogen 0.45 mg and bazedoxifene 20 mg) over 12 weeks reduced the average daily number of moderate and severe hot flushes by 7.6 compared with 4.9 for placebo. 
V študiji, v kateri so preučevali učinke na vročinske oblive, je zdravljenje z zdravilom Duavive (konjugirani estrogeni 0,45 mg in bazedoksifen 20 mg) v 12 tednih zmanjšalo povprečno dnevno število zmernih in hudih vročinskih oblivov za 7,6 v primerjavi s 4,9 pri placebu.
It must not be used in women who have had a stroke or heart attack. 
Zdravila Duavive prav tako ne smejo uporabljati ženske, ki so preživele možgansko kap ali srčni infarkt.
It is available as modified release tablets (containing 0.45 mg conjugated oestrogens and 20 mg bazedoxifene) which release bazedoxifene immediately and conjugated oestrogens over a longer period of time. 
Na voljo je v obliki tablet s prirejenim sproščanjem (vsebujejo 0,45 mg konjugiranih estrogenov in 20 mg bazedoksifena), iz katerih se bazedoksifen sprosti takoj, konjugirani estrogeni pa se sproščajo dlje časa.
Duavive contains two active substances: conjugated oestrogens and bazedoxifene. 
Zdravilo Duavive vsebuje dve zdravilni učinkovini: konjugirane estrogene in bazedoksifen.
How is Duavive used? 
Kako se zdravilo Duavive uporablja?
The study looking at the effects of Duavive on vulvovaginal atrophy found an improvement in some of the signs of vaginal atrophy but not in the most bothersome symptoms when compared with placebo. 
Študija, v kateri so proučevali učinke zdravila Duavive na vulvovaginalno atrofijo v primerjavi s placebom, je pokazala izboljšanje določenih znakov vaginalne atrofije, vendar ne najbolj motečih simptomov.
Duavive was shown to improve the symptoms caused by lack of oestrogen in postmenopausal women when compared with placebo. 
Dokazano je bilo, da zdravilo Duavive izboljša simptome, ki jih povzroča pomanjkanje estrogena pri ženskah po menopavzi, ko so ga primerjali s placebom.
Duavive can only be obtained with a prescription. 
Izdaja zdravila Duavive je le na recept.
Because studies with the higher strength combination did not sufficiently show that this strength was more effective than the approved strength of Duavive, the company withdrew its application for the former. 
Ker študije s kombinacijo večje jakosti niso prepričljivo pokazale, da je ta jakost učinkovitejša kot odobrena jakost zdravila Duavive, je družba umaknila vlogo za pridobitev dovoljenja za promet za zdravilo večje jakosti.
Similar results were seen with a higher strength of conjugated oestrogen (0.625 mg) plus bazedoxifene 20 mg when compared with placebo. 
Podobne rezultate je dalo zdravljenje s konjugiranim estrogenom večje jakosti (0,625 mg) skupaj z bazedoksifenom (20 mg), ko so ga primerjali z zdravljenjem s placebom.
How does Duavive work? 
Kako zdravilo Duavive deluje?
One of the studies also looked at the effects of Duavive on osteoporosis; however, as there was no benefit of Duavive over the individual components the company withdrew its application for Duavive in the treatment of osteoporosis. 
Ker pa zdravilo Duavive ni izkazalo večjih koristi kot posamezne sestavine, je družba umaknila svojo vlogo za zdravilo Duavive za indikacijo zdravljenja osteoporoze.
Further information on NovoEight can be found on the Agency's website: ema.europa.eu/en/medicines/human/EPAR/novoeight. 
Nadaljnje informacije za zdravilo NovoEight so na voljo na spletni strani agencije: ema.europa.eu/en/medicines/human/EPAR/novoeight.
What measures are being taken to ensure the safe and effective use of NovoEight? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila NovoEight?
The European Medicines Agency decided that NovoEight's benefits are greater than its risks and it can be authorised for use in the EU. 
Evropska agencija za zdravila je zaključila, da so koristi zdravila NovoEight večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
As for all medicines, data on the use of NovoEight are continuously monitored. 
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila NovoEight stalno spremljajo.
Hypersensitivity (allergic) reactions can occur rarely with NovoEight and may in some cases progress to severe allergic reactions. 
Pri zdravilu NovoEight se lahko redko pojavijo preobčutljivostne (alergijske) reakcije, ki se lahko v nekaterih primerih razvijejo v hude alergijske reakcije.
An overview of NovoEight and why it is authorised in the EU 
Pregled zdravila NovoEight in zakaj je odobreno v EU
What benefits of NovoEight have been shown in studies? 
Kakšne koristi zdravila NovoEight so se pokazale v študijah?
Other information about NovoEight 
Druge informacije o zdravilu NovoEight
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of NovoEight have been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila NovoEight upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
These inhibitors are antibodies that the immune system (the body's natural defences) produces against factor VIII. 
Ti zaviralci so protitelesa, ki jih imunski sistem (naravni obrambni mehanizem telesa) proizvede kot odziv proti faktorju VIII.
In the second study involving 63 children less than 12 years of age, children treated with NovoEight had an average of 5.33 bleeding episodes per year. 
V drugi študiji, ki je vključevala 63 otrok, mlajših od 12 let, so otroci, zdravljeni z zdravilom NovoEight, povprečno doživeli 5,33 krvavitve na leto.
NovoEight received a marketing authorisation valid throughout the European Union on 13 November 
Za zdravilo NovoEight je bilo 13. novembra 2013 izdano dovoljenje za promet, veljavno po vsej EU.
The dose and frequency of treatment depend on whether it is used to treat or prevent bleeding, as well as the seriousness of the haemophilia, the extent and location of the bleeding and the patient's age and condition. 
Odmerek in pogostnost injiciranja zdravila sta odvisna od tega, ali se uporablja za zdravljenje ali preprečevanje krvavitev, ter od resnosti hemofilije, obsega in mesta krvavitve ter bolnikove starosti in kliničnega stanja.
Side effects reported with NovoEight are carefully evaluated and any necessary action taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu NovoEight, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
For continuing treatment, the doctor may adjust the dose and frequency of injection according to the blood levels of factor VIII. 
Pri nadaljnjem zdravljenju lahko zdravnik prilagodi odmerek in pogostnost injiciranja glede na ravni faktorja VIII v krvi.
What is NovoEight and what is it used for? 
Kaj je zdravilo NovoEight in za kaj se uporablja?
Patients or their carers may be able to inject NovoEight themselves once they have been trained. 
Bolniki ali njihovi negovalci lahko po ustreznem usposabljanju zdravilo NovoEight injicirajo sami.
In the first study involving 150 patients aged 12 years and above, adolescents who used NovoEight to prevent bleeding had an average of 5.55 bleeding episodes per year and adults had an average of 6.68 bleeding episodes per year. 
V prvi študiji, ki je vključevala 150 bolnikov, starih 12 let in več, so mladostniki, ki so uporabljali zdravilo NovoEight za preprečevanje krvavitev, povprečno doživeli 5,55 krvavitve na leto, odrasli pa 6,68 krvavitve na leto.
NovoEight was effective at preventing and treating bleeding episodes in two main studies involving a total of 213 patients with haemophilia A. Neither study compared NovoEight with any other medicines. 
Zdravilo NovoEight je bilo učinkovito pri preprečevanju in zdravljenju krvavitev v dveh glavnih študijah, ki sta skupaj vključevali 213 bolnikov s hemofilijo A. V nobeni od teh študij zdravila NovoEight niso primerjali z nobenim drugim zdravilom.
The active substance in NovoEight, turoctocog alfa, works in the same way as natural factor VIII and helps the blood to clot. 
Učinkovina v zdravilu NovoEight, turoktokog alfa, deluje na enak način kot naravni faktor VIII in pomaga pri strjevanju krvi.
NovoEight is available for injection into a vein. 
Zdravilo NovoEight je na voljo za injiciranje v veno.
For more information about using NovoEight, see the package leaflet or contact your doctor or pharmacist. 
Za več informacij glede uporabe zdravila NovoEight glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
What are the risks associated with NovoEight? 
Kakšna tveganja so povezana z zdravilom NovoEight?
Why is NovoEight authorised? 
Zakaj je bilo zdravilo NovoEight odobreno?
In addition, 89.4% of the bleeding episodes resolved after 1 to 2 doses of NovoEight. 
Poleg tega se je 89,4 % krvavitev ustavilo po enem do dveh odmerkih zdravila NovoEight.
The safety profile of NovoEight was also considered similar to other factor VIII products. 
Varnostni profil zdravila NovoEight je prav tako podoben kot pri drugih zdravilih s faktorjem VIII.
When used for the treatment of spontaneous bleeding, NovoEight was rated as ‘excellent' or ‘good' at treating 403 of 499 of the bleeding episodes. 
Pri uporabi zdravila NovoEight za zdravljenje spontanih krvavitev je bilo to pri zdravljenju 403 od 499 krvavitev ocenjeno kot „izvrstno“ ali „dobro“.
In addition, 95.2% of the bleeding episodes resolved after 1 to 2 doses of NovoEight. 
Poleg tega se je 95,2 % krvavitev ustavilo po enem do dveh odmerkih zdravila NovoEight.
The medicine contains the active substance turoctocog alfa. 
Vsebuje učinkovino turoktokog alfa.
Some patients may develop factor VIII inhibitors, which can cause the medicine to stop working, resulting in a loss of bleeding control. 
Pri nekaterih bolnikih se lahko razvijejo zaviralci faktorja VIII, ki lahko onemogočijo delovanje zdravila, kar povzroči izgubo nadzora nad krvavitvami.
NovoEight can only be obtained with a prescription, and treatment should be started under the supervision of a doctor who has experience in the treatment of haemophilia. 
Predpisovanje in izdaja zdravila NovoEight je le na recept, zdravljenje z njim pa se sme uvesti samo pod nadzorom zdravnika z izkušnjami z zdravljenjem hemofilije.
NovoEight must not be used in patients who are allergic to hamster protein. 
Zdravilo NovoEight se ne sme uporabljati pri bolnikih z alergijo na beljakovine hrčka.
Patients with haemophilia A lack factor VIII, which prevents blood from clotting and can cause problems such as bleeding in the joints, muscles or internal organs. 
Bolnikom s hemofilijo A primanjkuje faktorja VIII, kar preprečuje strjevanje krvi in povzroči težave, kot so krvavenje v sklepe, mišice ali notranje organe.
NovoEight is used to correct the factor VIII deficiency by replacing the missing factor VIII, thereby giving temporary control of the bleeding disorder. 
Zdravilo NovoEight se uporablja za uravnavanje pomanjkanja faktorja VIII, in sicer z nadomeščanjem manjkajočega faktorja VIII, kar vzpostavi začasni nadzor nad krvavitvami.
The Agency concluded that NovoEight is effective for treating and preventing bleeding episodes, with effects similar to other factor VIII products. 
Menila je, da je zdravilo NovoEight učinkovito pri zdravljenju in preprečevanju krvavitev in da ima podobne učinke kot druga zdravila s faktorjem VIII.
How is NovoEight used? 
Kako se zdravilo NovoEight uporablja?
NovoEight is a medicine used to treat and prevent bleeding in patients with haemophilia A an inherited bleeding disorder caused by lack of factor VIII. 
NovoEight je zdravilo, ki se uporablja za zdravljenje in preprečevanje krvavitev pri bolnikih s hemofilijo A (dedno motnjo strjevanja krvi zaradi pomanjkanja faktorja VIII).
How does NovoEight work? 
Kako zdravilo NovoEight deluje?
NovoEight was rated as ‘excellent' or ‘good' at treating 116 of the 126 bleeding episodes. 
Pri zdravljenju 116 od 126 krvavitev je bilo zdravilo NovoEight ocenjeno kot „izvrstno“ ali „dobro“.
3.1 mg / 24 h Transdermal patch Transdermal use sachet (coated paper/alu/LLDPE) 
3,1 mg / 24 h transdermalni obliž transdermalna uporaba vrečica (prevlečen papir/aluminij/LLDPE)
(Invented) name 
(Izmišljeno ime)
1 patch 
1 obliž
Begin your treatment. 
Začnite zdravljenje.
Date of first authorisation: 21 September 2009 Date of latest renewal: 26 May 2016 
Datum prve odobritve: 21. september 2009 Datum zadnjega podaljšanja: 26. maja 2016
Sit in a relaxed, upright position. 
Sedite v sproščenem, ravnem položaju.
This may be more common in children than in adults. 
To je lahko pogosteje pri otrocih, kot pri odraslih.
Consideration should be given to official guidance on the appropriate use of antibacterial agents. 
Upoštevati je treba uradne smernice za ustrezno uporabo antibakterijskih učinkovin.
Currently available data are described in section 5.1 but no recommendation on posology can be given. 
Trenutno razpoložljivi podatki so opisani v poglavju 5.1, vendar priporočil o odmerjanju ni mogoče dati.
This makes it hard to breathe. 
To onemogoča dihanje.
Tell your doctor if you have any of these effects. 
Povejte svojemu zdravniku, če opazite katerega od teh učinkov.
Use this medicine immediately after preparation. 
To zdravilo uporabite takoj po pripravi.
After identical single i.m. 
Po identičnem enojnem odmerku i.m.
In healthy subjects 60-70% of a single i.m. 
Pri zdravih osebah je bilo 60-70% enkratnega i.m.
Overall, 539 patients (78% adults) were treated in these studies. 
V teh študijah so zdravili 539 bolnikov (78 % odraslih).
All these may be signs of an allergic reaction. 
To so lahko znaki alergijske reakcije.
However, all mean sputum concentration values were associated with relatively large standard deviations. 
Vendar pa so bile vse srednje vrednosti koncentracij v izpljunku povezane z relativno velikimi standardnimi odkloni.
In-use storage times and conditions prior to use are the responsibility of the user. 
Za shranjevanje med uporabo in pogoje pred uporabo je odgovoren uporabnik.
The following pack sizes are available: 
Na voljo so naslednje velikosti pakiranj:
If you notice that the performance has changed before this time (for instance, if it takes longer to produce a mist, more than 5 minutes), please refer to the Altera Nebuliser instructions for use. 
Če opazite, da se delovanje spremeni že pred koncem tega obdobja (če na primer nastajanje meglice traja dalj časa, več kot 5 minut), preberite navodila za uporabo nebulatorja Altera.
Frequencies are defined as follows: very common (≥ 1/10), common (≥ 1/100 to < 1/10) and uncommon (≥ 1/1000 to < 1/100). 
Pogostnosti pojavov so opredeljene kot sledi: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10) in občasni (≥ 1/1.000 do < 1/100).
- if you are allergic to aztreonam or any of the other ingredients of this medicine (listed in section 6). 
- če ste alergični na aztreonam ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
dose was recovered in the urine by 8 hours, and urinary excretion was essentially complete by 12 hours. 
odmerka najti v urinu po 8 urah, izločanje z urinom pa je bilo v glavnem zaključeno po 12 urah.
Use the prepared solution within 8 hours. 
Pripravljeno raztopino uporabite v 8 urah.
Reconstitute before use. 
Pred uporabo rekonstituirajte.
You will hear one “beep” and the status light will turn green. 
Zaslišali boste pisk in statusna lučka se bo spremenila na zeleno.
Recovery data indicate that about 10% of the dose is excreted as this metabolite. 
Podatki o izločanju kažejo, da se približno 10% odmerka izloči kot ta presnovek.
Carefully remove (but do not yet discard) the rubber stopper. 
Previdno odstranite gumijasti zamašek (vendar ga še ne zavrzite).
or i.v. 
ali i.v.
Refer to section 4.4. 
Glejte poglavje 4.4.
Do not prepare more than one dose at a time. 
Ne pripravite več kot enega odmerka hkrati.
If a case of bronchospasm is suspected to be part of an allergic reaction appropriate measures should be taken (see “allergic reactions” paragraph above). 
Če se sumi, da je primer bronhospazma del alergijske reakcije, je treba ustrezno ukrepati (glejte poglavje “Alergijske reakcije” poglavje zgoraj).
This leaflet was last revised in . 
Navodilo je bilo nazadnje revidirano dne .
This helps to ensure that you get the proper dose of medicine. 
S tem zagotovite pravilni odmerek zdravila.
This pack is not to be sold separately. 
Ta paket ni namenjen prodaji kot samostojna enota.
The survival rate during the lactation period was slightly reduced in the offspring of rats that received the highest dose. 
Stopnja preživetja v obdobju dojenja je bila nekoliko manjša pri podganjih mladičih, ki so prejemali najvišji odmerek.
doses, the serum concentrations are comparable at 1 hour (1.5 hours from the start of i.v. 
so koncentracije v serumu primerljive pri 1 uri (1,5 ure po začetku i.v.
Patients continued on their baseline medications, including macrolide antibiotics. 
Bolniki so nadaljevali jemanje izhodiščnih zdravil, vključno z makrolidnimi antibiotiki.
There are no data from the use of aztreonam in pregnant women. 
Ni podatkov o uporabi aztreonama pri nosečnicah.
The ampoule is imprinted in English only. 
Napis na ampuli je le v angleščini.
The safety and efficacy of Cayston in children younger than 6 years of age have not been established. 
Varnost in učinkovitost zdravila Cayston pri otrocih, mlajših od 6 let, še ni nista bili dokazani.
Hold the handset level and place the mouthpiece in your mouth and close your lips around it (Figure 4). 
Komplet z nebulatorjem držite ravno, dajte ustnik v usta in okoli njega zaprite ustnice (slika 4).
Patients were required to have been off antipseudomonal antibiotics for at least 28 days before treatment with study drug. 
Bolniki niso smeli prejemati antipsevdomonskih antibiotikov najmanj 28 dni pred zdravljenjem s študijskim zdravilom.
When all of the medicine has been delivered, you will hear a tone that means “treatment complete” (2 beeps). 
Ko je zdravilo porabljeno, boste slišali zvok, ki pomeni “konec zdravljenja” (2 piska).
What Cayston is and what it is used for 
Kaj je zdravilo Cayston in za kaj ga uporabljamo
Powder vial: 4 years. 
Viala s praškom: 4 leta Vehikel: 3 leta
Press and hold the On/Off button on the Control Unit for a few seconds. 
Pritisnite in nekaj sekund držite gumb za vklop/izklop na kontrolni enoti.
Do not reconstitute more than one dose at a time. 
Ne rekonstituirajte več kot enega odmerka hkrati.
infusion), with similar slopes of serum concentrations thereafter. 
infundiranja), s podobnimi kasnejšimi nakloni koncentracij v serumu.
Efficacy has not been established in patients with FEV1 > 75% predicted. 
Učinkovitosti pri bolnikih z napovedanim odstotkom FEV1 > 75% niso ugotavljali.
If you miss a dose, you can still take all 3 daily doses as long as they are at least 4 hours apart. 
Če izpustite odmerek, lahko še vedno uporabite vse 3 dnevne odmerke, če so med njimi vsaj 4-urni časovni presledki.
If you get a rash, tell your doctor immediately because this could mean that you have an allergic reaction to Cayston. 
Če dobite izpuščaj, takoj obvestite svojega zdravnika, saj lahko to pomeni alergijsko reakcijo na zdravilo Cayston.
However, due to the uncontrolled nature of the study and concomitant medications no conclusion can be drawn on the sustainability of the observed short term benefit over subsequent courses of treatment. 
Vendar zaradi nenadzorovanega poteka študije in sočasne uporabe drugih zdravil, ni mogoče sklepati o trajnosti opaženega kratkoročnega učinka v naslednjih ciklih zdravljenja.
Squeeze out the contents completely into the vial (Figure 2). 
Celotno vsebino stisnite v vialo (slika 2).
ESBLs from Class A, B and D beta-lactamases may have activity against aztreonam. 
ESBL iz betalaktamaz razredov A, B in D ima lahko dejavnost proti aztreonamu.
If you have ever coughed up blood you should only use Cayston if your doctor thinks the benefit of taking this medicine outweighs the risk of coughing up blood. 
Če ste kadar koli izkašljali kri, zdravilo Cayston uporabljajte samo, če zdravnik presodi, da so koristi uporabe tega zdravila večje od tveganj izkašljevanja krvi.
Each treatment takes about 2 to 3 minutes to inhale. 
Vsaka uporaba z inhaliranjem traja 2 do 3 minute.
Aztreonam, a monobactam, is only weakly immunogenic. 
Aztreonam, monobaktam, je le šibko imunogen.
The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal. 
C. DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET Z ZDRAVILOM Redno posodobljena poročila o varnosti zdravila (PSUR) Zahteve glede predložitve rednega posodobljenega poročila o varnosti zdravila za to zdravilo so določene v seznamu referenčnih datumov EU (seznamu EURD), opredeljenem v členu 107c(7) Direktive 2001/83/ES, in vseh kasnejših posodobitvah, objavljenih na evropskem spletnem portalu o zdravilih.
If an allergic reaction to aztreonam does occur, stop administration of the medicinal product and initiate treatment as appropriate. 
Če se pojavi alergijska reakcija na aztreonam, takoj nehajte uporabljati zdravilo in uvedite ustrezno zdravljenje.
The dosing in children aged 6 years and older is the same as for adults. 
Odmerjanje pri otrocih, starih 6 let in več, je enako kot pri odraslih.
The information that appears on the ampoule is presented below: 
Informacije na ampuli so navedene spodaj:
There was no clinically relevant effect of age or sex on the pharmacokinetics of aztreonam. 
Klinično pomembnega vpliva starosti ali spola na farmakokinetiko aztreonama ni.
Pharmacotherapeutic group: Antibacterials for systemic use, other beta-lactam antibacterials, ATC code: J01DF01 
Farmakoterapevtska skupina: Zdravila za sistemsko zdravljenje bakterijskih infekcij, drugi betalaktamski antibiotiki, oznaka ATC: J01DF01
Other medicines and Cayston 
Druga zdravila in zdravilo Cayston
The principal metabolite (SQ26,992) is inactive and is formed by opening of the beta-lactam ring due to hydrolysis. 
Glavni presnovek (SQ26,992) je neaktiven in nastane z odprtjem betalaktamskega obroča zaradi hidrolize.
Plasma concentrations 
Koncentracije v plazmi
• 28-day pack of Cayston 
• 28-dnevni paket zdravila Cayston
Class A betalactamases reported to hydrolyse aztreonam include the VEB type (primarily Southeast Asia), PER type (Turkey), and GES and IBC types (France, Greece, and S. Africa). 
Betalaktamaze razreda A, o katerih poročajo, da hidrolizirajo aztreonam, vključujejo tip VEB (primarno Jugovzhodna Azija), tip PER (Turčija) in tipa GES in IBC (Francija, Grčija in J. Afrika).
Doses should be taken at least 4 hours apart. 
Odmerke je treba uporabljati z vsaj 4-urnim razmakom.
Patients with Burkholderia cepacia isolated from sputum within the previous 2 years were excluded from the clinical studies. 
Bolniki, pri katerih so iz izpljunka izolirali povzročitelja Burkholderia cepacia v roku predhodnih 2 let, so bili izključeni iz kliničnih študij.
Inhalation of nebulised solutions may induce a cough reflex. 
Inhaliranje nebuliziranih raztopin lahko povzroči refleks kašlja.
Systemically absorbed aztreonam is eliminated about equally by active tubular secretion and glomerular filtration. 
Sistemsko absorbiran aztreonam se približno enakovredno izloči z aktivno tubularno sekrecijo in glomerularno filtracijo.
Do not use this medicine if it has been stored outside a refrigerator for more than 28 days. 
Ne uporabljajte tega zdravila, če je bilo shranjeno zunaj hladilnika več kot 28 dni.
The protein binding of aztreonam in plasma is approximately 77% at clinically relevant plasma concentrations. 
Vezava aztreonama na beljakovine v plazmi je približno 77% pri klinično pomembnih koncentracijah v plazmi.
For patients taking multiple inhaled therapies, the recommended order of administration is as follows: 
Za bolnike, ki uporabljajo več inhalacijskih terapij, se priporoča naslednji vrstni red uporabe: